Pulmonary Fibrosis Treatment Market – Overview Pulmonary fibrosis is a type of interstitial lung disorder. In this disease, the lung tissues are scarred and that leads to the reduction of oxygen exchange area of the lungs. Currently the root cause of the disease is still unknown. The medical science has put the disease into a non-reversible disease category and it has no permanent cure. However, with a proper pulmonary fibrosis treatment methods or drugs, the management of disease can last up to 2 to 5 years. Read Report Overview - https://www.transparencymarketresearch.com/pulmonary-fibrosis-treatmentmarket.html Pulmonary Fibrosis Treatment Market – Notable Developments Some of the recent notable developments in the global pulmonary fibrosis treatment market are listed down below: In 2014, apart from the conventional off-label corticosteroid treatment methods, drugs from different companies such as Boehringer Ingelheim Pharmaceuticals’ Ofev and Genentech Inc.’s Esbriet received approval for commercialization from the US FDA. In August 2019, EmphyCorp Inc. announced that the company has applied for the FDA approval for the NDA marketing of its non-steroidal nasal spray. This spray is used in the treatment of Interstitial Lung Diseases (ILD) that includes cystic fibrosis and pulmonary fibrosis. Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php? flag=B&rep_id=73748 In 2017, National Heart, Lung, and Blood Institute of the National Institutes of Health grant announced that it has awarded a grant of more than US$2.1 million to the researchers of the Weill Cornell Medicine for a period of four years to determine the mechanism of scarring of lung tissues. Pulmonary Fibrosis Treatment Market – Drivers and Restraints There are numerous factors that have a positive influence over the development of the global pulmonary fibrosis treatment market. One of the biggest driving factors for the growth of the global market has been the quick approval of novel drugs in the market. With the advances in technology and in the medical sciences, new and breakthrough therapies are now available in the market. This has also played a crucial role in the development of the global pulmonary fibrosis treatment market. Request for Analysis of COVID-19 Impact on Pulmonary Fibrosis Treatment Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73748 Another important driving factor for the growth of the market has been the growing incidences of pulmonary fibrosis has encouraged several medical and research institutes to undertake the studies to understand the root cause. This has led to the development of several new drugs and improve the diagnosis rate of the diseases. Naturally, it has helped in the development of the global pulmonary fibrosis treatment market. Pulmonary Fibrosis Treatment Market – Geographical Outlook